NewsGlobeNewswire
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
· Published
Article summary
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…